Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women?
Нема приказа
Аутори
Kovač, MirjanaMiković, Z.
Mitić, G.
Đorđević, Valentina
Jaglicić, I
Mandić, V
Radojković, Dragica
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Introduction:Optimal therapy in thrombophilic women with recur-rent fetal loss remains unclear.Aim:The study was conducted to point to the effect of anticoagulanttherapy (LMWH) in thrombophilic women and possible differenceamong women carriers of mutations (FVLeiden, FIIG20210,MTHFR) and women who had deficiency of natural anticoagulants.Material and Methods:Prospective study carried from 2007 to 2010,included 136 pregnant women, mean age 31 (range 20–42), with arecurrent fetal loss in previous pregnancies. They were included intheir early pregnancy and tested to thrombophilia presence. In 61(46.4%) the inherited thrombophilia was detected and they were trea-ted with prophylactic doses of LMWH included from 6 to 8 gestationweeks, followed throughout 70 pregnancies. The pregnancy outcomesin thrombophilic women were evaluated in comparison with group ofwomen without trhombophilia (31), who were followed without treat-ment throughout 36 pregnancies.Results:Among thrombophilic women,... despite the prophylactic ther-apy use, 10 (14.3%) pregnancies ended with fetal loss, while in thegroup without thrombophilia, five (11.9%) pregnancy losses wererecorded,P= 0.881. Regarding the type of thrombophila, high rateof live birth was observed in group of women with mutations(93.4%) and similar increase of D-dimer through gestational age like-wise in women without thrombophilia, while in women with defi-ciency of natural anticoagulants much higher haemostatic activity(P< 0.0001), and significantly lower chance of a live birth (33.3%),P= 0.0001 were observed.Conclusion:There is no evidence that the use of prophylactic dose ofLMWH improves the live birth in women with deficiency of naturalanticoagulants.Disclosure of Interest:We have no potential conflict of interest. Ourstudy was not supported or paid by any organization.
Извор:
Journal of Thrombosis and Haemostasis, 2011, 9, 173-173Издавач:
- Wiley-Blackwell, Hoboken
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Kovač, Mirjana AU - Miković, Z. AU - Mitić, G. AU - Đorđević, Valentina AU - Jaglicić, I AU - Mandić, V AU - Radojković, Dragica PY - 2011 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/514 AB - Introduction:Optimal therapy in thrombophilic women with recur-rent fetal loss remains unclear.Aim:The study was conducted to point to the effect of anticoagulanttherapy (LMWH) in thrombophilic women and possible differenceamong women carriers of mutations (FVLeiden, FIIG20210,MTHFR) and women who had deficiency of natural anticoagulants.Material and Methods:Prospective study carried from 2007 to 2010,included 136 pregnant women, mean age 31 (range 20–42), with arecurrent fetal loss in previous pregnancies. They were included intheir early pregnancy and tested to thrombophilia presence. In 61(46.4%) the inherited thrombophilia was detected and they were trea-ted with prophylactic doses of LMWH included from 6 to 8 gestationweeks, followed throughout 70 pregnancies. The pregnancy outcomesin thrombophilic women were evaluated in comparison with group ofwomen without trhombophilia (31), who were followed without treat-ment throughout 36 pregnancies.Results:Among thrombophilic women, despite the prophylactic ther-apy use, 10 (14.3%) pregnancies ended with fetal loss, while in thegroup without thrombophilia, five (11.9%) pregnancy losses wererecorded,P= 0.881. Regarding the type of thrombophila, high rateof live birth was observed in group of women with mutations(93.4%) and similar increase of D-dimer through gestational age like-wise in women without thrombophilia, while in women with defi-ciency of natural anticoagulants much higher haemostatic activity(P< 0.0001), and significantly lower chance of a live birth (33.3%),P= 0.0001 were observed.Conclusion:There is no evidence that the use of prophylactic dose ofLMWH improves the live birth in women with deficiency of naturalanticoagulants.Disclosure of Interest:We have no potential conflict of interest. Ourstudy was not supported or paid by any organization. PB - Wiley-Blackwell, Hoboken C3 - Journal of Thrombosis and Haemostasis T1 - Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women? EP - 173 SP - 173 VL - 9 UR - https://hdl.handle.net/21.15107/rcub_imagine_514 ER -
@conference{ author = "Kovač, Mirjana and Miković, Z. and Mitić, G. and Đorđević, Valentina and Jaglicić, I and Mandić, V and Radojković, Dragica", year = "2011", abstract = "Introduction:Optimal therapy in thrombophilic women with recur-rent fetal loss remains unclear.Aim:The study was conducted to point to the effect of anticoagulanttherapy (LMWH) in thrombophilic women and possible differenceamong women carriers of mutations (FVLeiden, FIIG20210,MTHFR) and women who had deficiency of natural anticoagulants.Material and Methods:Prospective study carried from 2007 to 2010,included 136 pregnant women, mean age 31 (range 20–42), with arecurrent fetal loss in previous pregnancies. They were included intheir early pregnancy and tested to thrombophilia presence. In 61(46.4%) the inherited thrombophilia was detected and they were trea-ted with prophylactic doses of LMWH included from 6 to 8 gestationweeks, followed throughout 70 pregnancies. The pregnancy outcomesin thrombophilic women were evaluated in comparison with group ofwomen without trhombophilia (31), who were followed without treat-ment throughout 36 pregnancies.Results:Among thrombophilic women, despite the prophylactic ther-apy use, 10 (14.3%) pregnancies ended with fetal loss, while in thegroup without thrombophilia, five (11.9%) pregnancy losses wererecorded,P= 0.881. Regarding the type of thrombophila, high rateof live birth was observed in group of women with mutations(93.4%) and similar increase of D-dimer through gestational age like-wise in women without thrombophilia, while in women with defi-ciency of natural anticoagulants much higher haemostatic activity(P< 0.0001), and significantly lower chance of a live birth (33.3%),P= 0.0001 were observed.Conclusion:There is no evidence that the use of prophylactic dose ofLMWH improves the live birth in women with deficiency of naturalanticoagulants.Disclosure of Interest:We have no potential conflict of interest. Ourstudy was not supported or paid by any organization.", publisher = "Wiley-Blackwell, Hoboken", journal = "Journal of Thrombosis and Haemostasis", title = "Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women?", pages = "173-173", volume = "9", url = "https://hdl.handle.net/21.15107/rcub_imagine_514" }
Kovač, M., Miković, Z., Mitić, G., Đorđević, V., Jaglicić, I., Mandić, V.,& Radojković, D.. (2011). Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women?. in Journal of Thrombosis and Haemostasis Wiley-Blackwell, Hoboken., 9, 173-173. https://hdl.handle.net/21.15107/rcub_imagine_514
Kovač M, Miković Z, Mitić G, Đorđević V, Jaglicić I, Mandić V, Radojković D. Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women?. in Journal of Thrombosis and Haemostasis. 2011;9:173-173. https://hdl.handle.net/21.15107/rcub_imagine_514 .
Kovač, Mirjana, Miković, Z., Mitić, G., Đorđević, Valentina, Jaglicić, I, Mandić, V, Radojković, Dragica, "Can anticoagulant therapy improve the outcome of pregnancy in thrombophilic women?" in Journal of Thrombosis and Haemostasis, 9 (2011):173-173, https://hdl.handle.net/21.15107/rcub_imagine_514 .